# US 2015/0031070 A1 · Optically sensitive cell network

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031070 A1
- Document ID: US20150031070A1
- Status: Published application
- Kind: A1
- Application number: 14/512,557
- Filed: 2014-10-13
- Published: 2015-01-29
- Earliest claimed: 2012-01-04
- Assignees: Technion Research & Development Foundation Limited
- Applicants: Technion Research & Development Foundation Limited
- Inventors: SHY SHOHAM; ANAT MAROM; SANJEEV KUMAR MAHTO
- Web page: https://patentgrep.com/patent/US20150031070A1

## CPC

- G01N 33/5058: {Neurological cells}
- A61B 17/1128: {of nerves}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61L 27/383: {Nerve cells, e.g. dendritic cells, Schwann cells}
- A61L 27/52: Hydrogels or hydrocolloids
- A61N 5/0622: {Optical stimulation for exciting neural tissue}
- C12M 31/00: {Means for providing, directing, scattering or concentrating light (C12M41/06 takes precedence)}
- C12N 5/0619: {Neurons}
- A61F 2230/0063: Three-dimensional shapes
- C12N 5/062: {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/33: Insulin
- C12N 2503/04: Screening or testing on artificial tissues
- C12N 2510/00: Genetically modified cells
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

A neural network is disclosed. The neural network comprises a plurality of optogenetically modified neural cells being three-dimensionally distributed in a hydrogel medium and being disconnected from any solid support having a shear modulus above 1 GPa.

## Claims

### Claim 1

A system for drug screening, comprising:
a chamber having therein the neural network which comprises a plurality of optogenetically modified neural cells being three-dimensionally distributed in a hydrogel medium and being disconnected from any solid support having a shear modulus above 1 GPa; and
a microfluidic system for supplying at least one drug to said cells.

### Claim 2 (depends on 1)

The system of claim 1, further comprising an imaging device constituted for imaging an activity of said neural cells while being in said chamber.

### Claim 3 (depends on 2)

The system of claim 2, wherein said imaging device is configured for 3D functional microscopy.

### Claim 4 (depends on 1)

The system according to claim 1, wherein said chamber is configured to allow imaging said neural cells from two opposite sides of said chamber.

### Claim 5 (depends on 1)

The system according to claim 1, further comprising an electrode system positioned in said neural network and configured for receiving signals from said neural cells responsively to optical stimulation of said neural cells.

### Claim 6 (depends on 1)

The system of claim 1, wherein said microfluidic system is constituted for supplying different drugs to different regions of said neural network.

### Claim 7 (depends on 1)

The system of claim 1, further comprising an optical stimulation device configured for optically stimulating said neural network.

### Claim 8 (depends on 7)

The system of claim 7, wherein said optical stimulation device is a 3D optical stimulation system.

### Claim 9 (depends on 8)

The system of claim 8, wherein said 3D optical stimulation system is a holography system.

### Claim 10 (depends on 1)

The system of claim 1, further comprising a porous membrane positioned to spatially separate said neural network from said microfluidic system.

### Claim 11 (depends on 10)

The system of claim 10, wherein said microfluidic system comprises microchannels shaped as trenches with an open facet engaged by said membrane.

### Claim 12 (depends on 2)

The system of claim 2, further comprising a base structure configured for holding said neural network therein.

### Claim 13 (depends on 12)

The system of claim 12, wherein said base structure is exposed to a culture medium for supplying of nutrients to said neural cells.

### Claim 14 (depends on 13)

The system of claim 13, further comprising a porous membrane positioned such that said base structure and said culture medium are at one side of said membrane and said microfluidic system is on an opposite side of said membrane.

### Claim 15

A method of drug screening, comprising:
using a microfluidic system for supplying at least one drug to a neural network contained in a chamber, said neural network comprising a plurality of optogenetically modified neural cells being three-dimensionally distributed in a hydrogel medium and being disconnected from any solid support having a shear modulus above 1 GPa;
optically stimulating said neural network; and
imaging said neural cells to determine activity of said neural cells and/or response of neural cells to said stimulation.

### Claim 16 (depends on 15)

The method according to claim 15, further comprising collecting electrical signals from said neural cells responsively to said optical stimulation.

### Claim 17 (depends on 15)

The method of claim 15, wherein said supplying at least one drug comprises supplying different drugs to different regions of said neural network.

### Claim 18 (depends on 15)

The method of claim 15, further comprising supplying nutrition to said neural network.

### Claim 19 (depends on 18)

The method of claim 18, wherein said neural network is spatially separated from said microfluidic system by a porous membrane, and wherein said supplying at least one drug is executed at one side of said membrane and said supplying said nutrition is executed at an opposite side of said membrane.

### Claim 20 (depends on 15)

The method of claim 15, wherein said microfluidic system comprises a plurality of ports and a plurality of microchannels, wherein each microchannel of said plurality of microchannels extend from an inlet port of said plurality of ports to an outlet port of said plurality of ports, and wherein said supplying said at least one drug is via said inlet port.
